Pexiganan
- Generic Name
- Pexiganan
- Drug Type
- Small Molecule
- Chemical Formula
- C122H210N32O22
- CAS Number
- 147664-63-9
- Unique Ingredient Identifier
- TVF29Q70Q1
- Background
Pexiganan is under investigation in clinical trial NCT01594762 (Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers).
Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
Phase 3
Completed
- Conditions
- Diabetic Foot Infection
- Interventions
- First Posted Date
- 2012-05-09
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- Dipexium Pharmaceuticals, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT01594762
Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
Phase 3
Completed
- Conditions
- Diabetic Foot Infection
- Interventions
- First Posted Date
- 2012-05-03
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- Dipexium Pharmaceuticals, Inc.
- Target Recruit Count
- 189
- Registration Number
- NCT01590758
MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers
- First Posted Date
- 2007-11-26
- Last Posted Date
- 2020-09-03
- Lead Sponsor
- Abeona Therapeutics, Inc
- Target Recruit Count
- 342
- Registration Number
- NCT00563433
- Locations
- 🇺🇸
Seattle VA Medical Center, Seattle, Washington, United States
MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers
- First Posted Date
- 2007-11-26
- Last Posted Date
- 2020-09-03
- Lead Sponsor
- Abeona Therapeutics, Inc
- Target Recruit Count
- 584
- Registration Number
- NCT00563394
- Locations
- 🇺🇸
Seattle VA Medical Center, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath